Study of GLP-1 drug effects on microvascular outcomes examines protection of small blood vessels in eyes, kidneys, and nerves in diabetes.
Key findingStudy of GLP-1 drug effects on microvascular outcomes examines protection of small blood vessels in
What the researchers found
Study of GLP-1 drug effects on microvascular outcomes examines protection of small blood vessels in eyes, kidneys, and nerves in diabetes.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
4 RCTs included, over 27,000 patients total. Follow-up: 32 weeks to 5.4 years. Consistent renal protection; possible retinopathy signal.
How the study worked
In publication.
Who was studied
Adults with type 2 diabetes across four large randomized controlled trials
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review of Retinopathy and Nephropathy Evidence.
Cureus, 17(9), e92976
Citation
Arif, Atia; Lama, Sanu; Singla, Bhavna; Singla, Shivam; Kumawat, Sunita; Tharwani, Anusha; Usman, Muhammad; Khalid, Hamna; Kanukollu, Venkata Madusudana Rao; Ekomwereren, Osatohanmwen; Khan, Shabir. (2025). Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review of Retinopathy and Nephropathy Evidence.. Cureus, 17(9), e92976. https://doi.org/10.7759/cureus.92976